Main Menu

Relocation follows fund raising

Peanut allergy firm moves to BioCity incubator

Diane Harbison BioCityScottish pharmaceuticals company Alfacyte is moving to the life sciences incubator BioCity Scotland on the eastern fringe of Glasgow after securing £350,000  to develop an oral vaccine for the treatment of peanut allergy.

Alfacyte, currently based in the city, was set up by Professor of Immunology William Stimson and Dr Alistair Strachan in 2012 with the aim of developing drug therapies to treat various food allergies.

It raised the equity and grant funding from the EOS Technology Investment Syndicate, Scottish Investment Bank and Scottish Enterprise in the summer. The investment will directly fund development and production of the proprietary molecule that will form the basis of a peanut allergy vaccine.

Gillian Brown, Alfacyte’s chief executive said: “As a very young and very small SME, we feel BioCity offers not just excellent facilities but an opportunity to mix with similar companies and share experiences. BioCity is more than just a location for our business, we can also benefit from the support and knowledge of its team and its network.”

Dr Diane Harbison (pictured), managing director of BioCity Scotland said: “Alfacyte is a tremendously exciting and innovative young company and I am delighted that they have chosen to come to BioCity Scotland.

“Food allergies are a very common life-limiting condition, especially in children, and cause hundreds of fatalities every year, so the development of an oral vaccine to treat peanut allergy has the potential to change thousands of lives all over the world. We look forward to supporting the ongoing development of the company here at BioCity Scotland.”

Dr Harbison added: “BioCity Scotland will become Scotland’s fifth Enterprise Area next year, which means that as well as providing our tenant companies with high spec laboratories and office space, access to expertise, finance and a community of like-minded people, we can also offer them business rates relief, faster planning applications and support and assistance in accessing international markets.”

Share The News Tweet about this on TwitterShare on FacebookShare on Google+Email this to someoneShare on LinkedIn





Leave a Reply

Your email address will not be published. Required fields are marked as *

*